Real-world evidence of galcanezumab for migraine treatment in Japan: a retrospective analysis.

ABSTRACT:

Objective

To evaluate the efficacy and safety of galcanezumab in patients with migraine in a real-world setting in Japan.

Background

Galcanezumab is the first anti-calcitonin gene-related peptide monoclonal antibody approved in Japan. To the best of our knowledge, no real-world studies on galcanezumab have been published in any international journal from Japan.

Methods

We retrospectively examined patients with migraine who received three doses of galcanezumab between August 2021 and February 2022 at the Keio University Hospital. We assessed changes in monthly migraine days, responder rate, and migraine-associated and premonitory symptoms. We also investigated injection site reactions and adverse events.

Results

Fifty-two patients received three doses of galcane

SUBMITTER: Takizawa T 

PROVIDER: S-EPMC9805082 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature